Home > Browse Issues > Vol.36 No.9
Anti-hepatoma Effect Study of Curcumin Derivative EF25-(GSH)2
Ye Lili1, Zhou Tao1, James P. Snyder2, Fu Haian3, Huang Bei1*
1College of Life Science, Anhui University, Hefei 230601, China; 2Department of Chemistry, Emory University, Atlanta 30322, USA; 3School of Medicine, Emory University, Atlanta 30322, USA
Abstract: EF25-(GSH)2 is a curcumin analogue， and in this research we will study its anti-hepatoma effect in vitro and in vivo. Hepatoma cells， normal liver cells and HepG2 tumor-bearing nude mice were treated with different concentrations of EF25-(GSH)2. MTT assay was used to check cell viability， and cell morphology was observed with an electron microscope and confocal microscopy. Western blot was used to detect the changes in the phosphorylation level of AMPK/Akt/mTOR pathway related proteins. The results showed that the IC50 of EF25-(GSH)2 on HepG2 at 48 h was 7.2 μmol/L. EF25-(GSH)2 significantly inhibited the growth of HepG2 cells， the effect of which was much greater than those of curcumin and cisplatin， with slight toxicity to normal cells. Autophagy was observed with morphorlogical analysis. Western blot results indicated that EF25-(GSH)2 might inhibit tumor cell growth through AMPK/Akt/mTOR pathway. Liver cancer models in nude mice were established， and tumor volume was reduced after administration of EF25-(GSH)2. In vitro and in vivo results demonstrate that EF25-(GSH)2 has good prospects as a potential anti-hepatoma drug.
CN
EN